creativemedicaltechnology.com (CELZ) Short-Term Debt to Capital
The linear price action on the Creative Medical Technology (CELZ) chart correlates with the development of cell therapy partnerships and the implementation of the ImmCelz system, with the indicator standing at 0.00. The continuity of research is guaranteed by functional cryo-equipment and high utilization of engineering capacities. The business relies on its own patent portfolio, creating regenerative medications for the therapy of immune and urological pathologies in the US.
Analytical breakdowns for Creative Medical Technology Holdings Inc. (CELZ)
When assessing the resilience of Creative Medical Technology (CELZ) to market shocks, it is essential to consider that the development of the AmnioStem platform and its patent portfolio requires stable funding; therefore, the chart of the ratio of short-term liabilities to equity, which measures the proportion of obligations with a maturity of over one year relative to equity, serves as a key indicator of the company's solvency and the reliability of its financial leverage.